Q: Does tesamorelin affect blood sugar?

This is the question the trials were built to watch, because growth hormone moves glucose. In the 2019 liver trial the primary safety endpoint was glucose, and at the end of it changes in fasting glucose and glycated haemoglobin were not different between groups at 12 months. Glycated haemoglobin is roughly the three-month average of blood sugar. The 2008 extension reports the same thing across a full year, recording that changes in glucose parameters over 52 weeks were not clinically significant and similar to those after 26 weeks. A 2024 trial in participants taking integrase inhibitors went looking for a problem and found a similar frequency of adverse events, including hyperglycemia, between groups. Hyperglycemia means blood sugar running high. All of that establishes that glucose did not move detectably in these trials, in patients screened to enter them. It is not a statement about somebody with diabetes, because the trials did not enrol one.

Q: What happens at the injection site?

Local reactions are the most consistently reported event on this compound. The 2019 liver trial records that individuals in the tesamorelin group experienced more localised injection site complaints than those in the placebo group, though none were judged to be serious. That is a comparison against placebo, which matters, because a placebo injection also produces complaints. The finding is that there were more of them, rather than that they existed at all. A 2011 review places injection-site reactions at the head of its own list, alongside the growth-hormone events. The published protocols are daily subcutaneous injections, so the site is used again and again over months. None of the studies covered here reports what rotation, needle size or technique did to that rate, because none of them varied any of those things.

Q: Why do these events look like growth hormone events?

Because the compound works by raising growth hormone, and a body does not sort a wanted effect from an unwanted one. A 2011 review describes tesamorelin as an analogue that stimulates the synthesis and release of endogenous growth hormone, endogenous meaning the hormone a body already makes. A 2026 meta-analysis confirms the signal arrives, finding that Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy. IGF-1 is the blood marker that tracks growth hormone output. So when a review reports growth hormone-related adverse effects, it is naming the other half of that same rise. Joint pain, swelling and headache are what extra growth hormone does, and they arrive alongside the change in body fat rather than instead of it. That is the frame for reading any adverse-event list on this compound. These are not side effects in the sense of being unrelated. They are the same signal, measured somewhere the reader did not want it.

Q: Who was excluded from these trials?

This is the part almost nobody publishes, and it decides how far the safety record carries. Every trial here enrolled adults with HIV. In the 2007 programme the investigators randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat, so the record is overwhelmingly male. The 2025 cognition trial states its exclusions outright, listing conditions other than HIV causing NCI, active substance use disorder, and malignancy, where NCI stands for neurocognitive impairment. The liver trial required people with HIV infection and a hepatic fat fraction (HFF) of 5% or more by proton magnetic resonance spectroscopy, which is a scan threshold, so anyone without measurable liver fat was not in it. A 2026 trial protocol describes its own population as 100 sedentary older adults (aged 50-80 years) living with HIV who are frail or at risk for frailty. Put together, the adverse-event record covers adults with HIV, mostly men, screened for other illness. Anybody outside that description is not represented in it.

Q: What is on record for the liver?

More than for most organs, because one trial went looking. A 2012 drug record states that tesamorelin has not been linked to serum aminotransferase elevations during therapy or to instances of clinically apparent acute liver injury. Those are the enzymes measured on a routine liver panel. The 2019 randomised trial went past enzymes and took tissue. In it, after 12 months, 35% of individuals receiving tesamorelin and 4% receiving placebo had a HFF of less than 5%, with HFF being the proportion of the liver that is fat. A 2020 analysis of biopsies from that trial found that in those participants tesamorelin decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division. That is a gene reading in tissue rather than a clinical outcome. The trial's own authors wrote that further studies are needed to determine the long-term effects of tesamorelin on liver histology.

Q: Is there anything on record about tumour risk?

Very little, and what there is needs reading carefully. The only entry among the sources covered here that touches the question is a 2020 analysis of liver biopsies taken during a randomised trial, which reports that tesamorelin also reciprocally up- and downregulated curated gene sets associated with favorable and poor hepatocellular carcinoma prognosis, respectively. Hepatocellular carcinoma is the common form of liver cancer, and a curated gene set is a list of genes assembled from earlier work. That sentence describes the direction gene activity moved in liver tissue over twelve months. It is not a count of cancers, in either direction, and it cannot be read as one. None of the trials covered here was built or sized to detect a tumour outcome, and none of them followed anybody long enough for the question to be answerable. The honest position is that it is open rather than settled either way.

Q: What is known about interactions with HIV medicines?

One trial was built to answer that. Integrase inhibitors are a class of HIV therapy brought in after the first tesamorelin trials were run. A 2024 report supplies the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens, where PWH means people with HIV. Among 38 participants on INSTI-based regimens at baseline, 15 individuals on tesamorelin and 16 individuals on placebo completed the 12-month study. The report found a similar frequency of adverse events between the two groups. Thirty-one people finishing is a small number for a safety comparison, and the authors frame the result as a first one rather than a settled one. Beyond that single question, none of the studies covered here tested tesamorelin against another medicine or compound. So interactions outside HIV therapy are unmeasured rather than ruled out.

Question 1

Is tesamorelin FDA approved, and what did that approval review?

Accepted Answer

Yes, once, for one diagnosis, and the detail of what was approved is the useful part. A 2011 note in Nature Reviews Drug Discovery records the decision. It dates the decision to November 2010, when tesamorelin was approved by the US Food and Drug Administration. The indication attached to it is the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. So what a regulator reviewed is a risk-and-benefit question about one molecule, in one group of patients, at one schedule, made by one firm. A 2012 review describes what the safety evidence was. It rested on two Phase 3 clinical trials and their pooled analyses, with 26-week extension phases that confirmed maintenance of VAT improvements on treatment without adverse impact on blood glucose and lipid parameters. An approval is a statement about that package. It is not a general verdict on the molecule, and it carries nothing at all to a vial sold without a label.

Question 2

What adverse events were recorded in the trials?

Accepted Answer

Two groups of them, and the reviews name both. A 2011 review in Drugs records that most of these events were injection-site reactions or events known to be associated with growth hormone therapy (e.g. arthralgia, headache and peripheral oedema). Arthralgia means joint pain, and peripheral oedema means fluid swelling in the hands, feet or ankles. A companion review published the same year reports the same split across the two 26-week trials behind the approval. A 2026 systematic review found that signature again in the pooled data, recording growth hormone-related adverse effects across four trials. Notice what that phrase does and does not say, because it says the events look like the ones growth hormone itself produces, which is what a compound acting through growth hormone would be expected to produce. It does not establish how often any single event turned up outside the trials that counted it.

Question 3

How often were serious events recorded?

Accepted Answer

The headline figure comes from the two trials behind the approval. A 2011 review reports treatment-emergent serious adverse events occurring in <4% of patients during 26 weeks of therapy. That is a rate over half a year, in patients under trial supervision, rather than a lifetime figure. A 2008 extension followed the same population for a second 26 weeks and found that the prevalence of adverse events and serious adverse events during the extension phase was comparable with the initial phase. Comparable is doing real work in that sentence, because it means the second half of the year looked like the first and says nothing at all about a third half-year, none of which was run. A 2026 systematic review adds the discontinuation signal, reporting higher discontinuation rates (RR2.25,95%CI[0.98,5.17],p=0.06) across the pooled trials. That interval crosses one, so the difference has not been separated from chance.

Question 4

Does tesamorelin affect blood sugar?

Accepted Answer

This is the question the trials were built to watch, because growth hormone moves glucose. In the 2019 liver trial the primary safety endpoint was glucose, and at the end of it changes in fasting glucose and glycated haemoglobin were not different between groups at 12 months. Glycated haemoglobin is roughly the three-month average of blood sugar. The 2008 extension reports the same thing across a full year, recording that changes in glucose parameters over 52 weeks were not clinically significant and similar to those after 26 weeks. A 2024 trial in participants taking integrase inhibitors went looking for a problem and found a similar frequency of adverse events, including hyperglycemia, between groups. Hyperglycemia means blood sugar running high. All of that establishes that glucose did not move detectably in these trials, in patients screened to enter them. It is not a statement about somebody with diabetes, because the trials did not enrol one.

Question 5

What happens at the injection site?

Accepted Answer

Local reactions are the most consistently reported event on this compound. The 2019 liver trial records that individuals in the tesamorelin group experienced more localised injection site complaints than those in the placebo group, though none were judged to be serious. That is a comparison against placebo, which matters, because a placebo injection also produces complaints. The finding is that there were more of them, rather than that they existed at all. A 2011 review places injection-site reactions at the head of its own list, alongside the growth-hormone events. The published protocols are daily subcutaneous injections, so the site is used again and again over months. None of the studies covered here reports what rotation, needle size or technique did to that rate, because none of them varied any of those things.

Question 6

Why do these events look like growth hormone events?

Accepted Answer

Because the compound works by raising growth hormone, and a body does not sort a wanted effect from an unwanted one. A 2011 review describes tesamorelin as an analogue that stimulates the synthesis and release of endogenous growth hormone, endogenous meaning the hormone a body already makes. A 2026 meta-analysis confirms the signal arrives, finding that Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy. IGF-1 is the blood marker that tracks growth hormone output. So when a review reports growth hormone-related adverse effects, it is naming the other half of that same rise. Joint pain, swelling and headache are what extra growth hormone does, and they arrive alongside the change in body fat rather than instead of it. That is the frame for reading any adverse-event list on this compound. These are not side effects in the sense of being unrelated. They are the same signal, measured somewhere the reader did not want it.

Question 7

Who was excluded from these trials?

Accepted Answer

This is the part almost nobody publishes, and it decides how far the safety record carries. Every trial here enrolled adults with HIV. In the 2007 programme the investigators randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat, so the record is overwhelmingly male. The 2025 cognition trial states its exclusions outright, listing conditions other than HIV causing NCI, active substance use disorder, and malignancy, where NCI stands for neurocognitive impairment. The liver trial required people with HIV infection and a hepatic fat fraction (HFF) of 5% or more by proton magnetic resonance spectroscopy, which is a scan threshold, so anyone without measurable liver fat was not in it. A 2026 trial protocol describes its own population as 100 sedentary older adults (aged 50-80 years) living with HIV who are frail or at risk for frailty. Put together, the adverse-event record covers adults with HIV, mostly men, screened for other illness. Anybody outside that description is not represented in it.

Question 8

What is on record for the liver?

Accepted Answer

More than for most organs, because one trial went looking. A 2012 drug record states that tesamorelin has not been linked to serum aminotransferase elevations during therapy or to instances of clinically apparent acute liver injury. Those are the enzymes measured on a routine liver panel. The 2019 randomised trial went past enzymes and took tissue. In it, after 12 months, 35% of individuals receiving tesamorelin and 4% receiving placebo had a HFF of less than 5%, with HFF being the proportion of the liver that is fat. A 2020 analysis of biopsies from that trial found that in those participants tesamorelin decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division. That is a gene reading in tissue rather than a clinical outcome. The trial's own authors wrote that further studies are needed to determine the long-term effects of tesamorelin on liver histology.

Question 9

Is there anything on record about tumour risk?

Accepted Answer

Very little, and what there is needs reading carefully. The only entry among the sources covered here that touches the question is a 2020 analysis of liver biopsies taken during a randomised trial, which reports that tesamorelin also reciprocally up- and downregulated curated gene sets associated with favorable and poor hepatocellular carcinoma prognosis, respectively. Hepatocellular carcinoma is the common form of liver cancer, and a curated gene set is a list of genes assembled from earlier work. That sentence describes the direction gene activity moved in liver tissue over twelve months. It is not a count of cancers, in either direction, and it cannot be read as one. None of the trials covered here was built or sized to detect a tumour outcome, and none of them followed anybody long enough for the question to be answerable. The honest position is that it is open rather than settled either way.

Question 10

What is known about interactions with HIV medicines?

Accepted Answer

One trial was built to answer that. Integrase inhibitors are a class of HIV therapy brought in after the first tesamorelin trials were run. A 2024 report supplies the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens, where PWH means people with HIV. Among 38 participants on INSTI-based regimens at baseline, 15 individuals on tesamorelin and 16 individuals on placebo completed the 12-month study. The report found a similar frequency of adverse events between the two groups. Thirty-one people finishing is a small number for a safety comparison, and the authors frame the result as a first one rather than a settled one. Beyond that single question, none of the studies covered here tested tesamorelin against another medicine or compound. So interactions outside HIV therapy are unmeasured rather than ruled out.

Question 11

What is known about longer-term risk?

Accepted Answer

The published exposure stops at a year. A 2008 extension ran the first trial out to 52 weeks and reports that the change in VAT was sustained at -18% over 52 weeks of treatment, with adverse events at the same prevalence as in the first half. Past that point the reviews all say the same thing in their own words. A 2011 review states that long-term clinical experience is needed to further assess the benefits and risks of therapy, and a 2012 review lists the practical limits as high cost and lack of long-term safety and adherence data. A 2026 systematic review repeats the point, noting that limited data on long-term safety, optimal dosing strategies, and durability of treatment effects warrant caution. Three reviews across fifteen years saying the same thing is itself the finding, because the gap has not closed and a year remains the edge of what these sources contain.

Question 12

What is documented in people without HIV?

Accepted Answer

One trial, and it was not a safety trial. A 2014 trial enrolled 39 obese men and women with reduced GH secretion as determined by GHRH-arginine stimulation tests. That trial ran for 12 months, double-blind, randomized, placebo-controlled, comparing tesamorelin vs placebo. Its endpoint was a scan measure of muscle energy recovery, not a table of adverse events. Everything else in the published record enrolled adults with HIV. So the profile a reader will find quoted anywhere, this page included, was watched in a group picked for one diagnosis, screened for others, and supervised all the way through. Whether the same profile turns up in an adult without HIV is unmeasured rather than reassuring. That distinction is the whole of the honest answer. Nothing among these sources turns a safety record from one group into a statement about another.

Question 13

Is tesamorelin legal in the United States?

Accepted Answer

As an approved prescription injection, yes, and that is a different question from whether any given vial is legal to sell. The approved version is dispensed against a prescription, and a 2016 reimbursement review records the submitted price is $3,085 per box of 60 vials (30-day supply), which is a pharmacy transaction with a payer behind it. Compounded versions are prepared by a pharmacy instead of being released against an approved label, and the FDA enforcement file holds two of those. Separately, the class is barred from competitive sport, since a 2021 paper records that the administration of growth hormone releasing hormone (GHRH) and its synthetic analogs is prohibited by the World Anti-Doping Agency (WADA). Legal status, approval status and anti-doping status are three different registers, and one compound can sit in a different place in each of them. Tesamorelin does.

Question 14

Does a compounded vial carry the same assurances?

Accepted Answer

No, and the enforcement file is the clearest way to see it. It holds a 2018 recall of Tesamorelin, 1mg/vial, 6mL vial, Lyophilized Powder for Reconstitution and Subcutaneous Injection from a Kentucky compounder, pulled because the vial indicates a 1 year expiration date instead of a 6 month expiration date. Lyophilized means freeze-dried. A second entry, from 2025, covers Tesamorelin for Injection, 15mg, 10 mL Multi-Dose Vial from a Florida firm, withdrawn for lack of assurance of sterility. Both sit on the record as Class II. Neither entry says anything about the molecule. One concerns sterility and the other concerns a printed date. That is exactly the point of reading them. The trials above tested an injection made to a filed specification, and nothing in them describes what is inside a vial made somewhere else. The schedule those trials used, and who received it, belongs to the Tesamorelin dosage page.

Tesamorelin side effects and safety data